Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: May 28, 2026

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies

Published on: July 28, 2020

Systemic management strategies for metastatic soft tissue sarcoma.

Sujana Movva1, Claire Verschraegen

  • 1Emory University, Atlanta, GA, USA.

Drugs
|November 1, 2011
PubMed
Summary

Soft tissue sarcomas, rare adult tumors, are managed with chemotherapy. Established treatments like doxorubicin are evolving with newer agents and targeted therapies for improved outcomes.

Related Concept Videos

Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Phase 2 dose-expansion trial of OBI-3424, a DNA-alkylating prodrug, in patients with advanced solid tumors expressing AKR1C3.

The oncologist·2026
Same author

Concomitant Medication Effects on Immunotherapy Outcomes in Sarcoma: A Pooled Post Hoc Analysis of Seven Phase II Trials.

Cancer medicine·2026
Same author

How the Ketogenic Diet Shapes the Microbiome to Influence Cancer Immunotherapy Outcomes: An Exploration of Clinical Trials and Their Results.

Nutrition and cancer·2026
Same author

Phase 2 study of palbociclib plus retifanlimab in patients with advanced dedifferentiated liposarcoma.

Journal for immunotherapy of cancer·2026
Same author

Novel Immunotherapeutic Approaches for Patients with Head and Neck Cutaneous Squamous Cell Carcinoma.

Oncology research·2026
Same author

Clinical Importance of Molecular Biomarkers in Pleural Mesothelioma.

Cancers·2026

Area of Science:

  • Oncology
  • Medical Research

Background:

  • Soft tissue sarcomas are rare adult malignancies necessitating a multidisciplinary care approach.
  • Chemotherapy remains the primary treatment for metastatic soft tissue sarcomas.

Purpose of the Study:

  • To review current and emerging therapeutic strategies for soft tissue sarcomas.
  • To highlight the role of traditional chemotherapy, novel agents, and targeted molecular therapies.

Main Methods:

  • Literature review of established and investigational treatments for soft tissue sarcomas.
  • Analysis of chemotherapy efficacy in specific subtypes like leiomyosarcoma and angiosarcoma.
  • Exploration of targeted therapies based on molecular aberrations.

Main Results:

  • Doxorubicin, ifosfamide, and dacarbazine are historical chemotherapy backbones.
  • Gemcitabine, docetaxel, paclitaxel, trabectedin, and eribulin show activity in specific subtypes.
  • Palifosfamide presents a potential safer alternative to ifosfamide.
  • Targeted agents inhibiting IGF-1R, mTOR, and VEGF are under investigation.

Conclusions:

  • Current management relies on established chemotherapies, with emerging roles for newer agents in specific sarcoma subtypes.
  • Future treatment paradigms may incorporate targeted therapies based on identified molecular targets.
  • Continued research is crucial for optimizing soft tissue sarcoma management.

More Related Videos

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

Related Experiment Videos

Last Updated: May 28, 2026

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies

Published on: July 28, 2020

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018